Company intelligence / Profile preview
XTL Biopharmaceuticals Ltd.
Ramat Gan, Israelxtlbio.com ↗
- Ownership
- Public · XTLB
- Employees
- ~7
- Development stage
- Phase 2
01
Overview
The company has two main product candidates: hCDR1 for SLE which has completed three clinical trials involving more than 400 patients, and recombinant Erythropoietin (rHuEPO) for multiple myeloma which received orphan drug designation from the FDA in 2011. In March 2025, XTL entered into a sublicense agreement with Biossil Inc. for its hCDR1 peptide.
- Therapeutic areas
- OncologyImmunologyEndocrinologyInfectious Diseases
- Modalities
- Synthetic peptidesMonoclonal antibodiesSmall moleculesRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Biossil Inc. (sublicense agreement for hCDR1)Yeda Research and Development Company Limited (licensing agreement for hCDR1)Cubist Pharmaceuticals (out-licensed HepeX-B)
04
Financials
- Market cap
- $2.3M
- Total revenue
- $289K
- Enterprise value
- $2.4M
Beyond the preview
Go deeper on XTL Biopharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XTL Biopharmaceuticals Ltd..